ロード中...
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation
PURPOSE AND DESIGN: Mechanism(s) by which the multi-kinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal and pancreatic adenocarcinoma cells have been defined. RESULTS: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic f...
保存先:
主要な著者: | , , , , , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
2008
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2561272/ https://ncbi.nlm.nih.gov/pubmed/18765530 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0469 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|